Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 170 200 KRW 2.1% Market Closed
Market Cap: 1.9T KRW
Have any thoughts about
Green Cross Corp?
Write Note

Green Cross Corp
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Green Cross Corp
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Depreciation & Amortization
-â‚©14.1B
CAGR 3-Years
-24%
CAGR 5-Years
-20%
CAGR 10-Years
-14%
Celltrion Inc
KRX:068270
Depreciation & Amortization
-â‚©162.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Depreciation & Amortization
-â‚©5.8B
CAGR 3-Years
-29%
CAGR 5-Years
-140%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Depreciation & Amortization
-â‚©9.3B
CAGR 3-Years
-10%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Depreciation & Amortization
-â‚©8.4B
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Depreciation & Amortization
-â‚©818.8m
CAGR 3-Years
N/A
CAGR 5-Years
-31%
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
216 615.19 KRW
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Depreciation & Amortization?
Depreciation & Amortization
-14.1B KRW

Based on the financial report for Sep 30, 2024, Green Cross Corp's Depreciation & Amortization amounts to -14.1B KRW.

What is Green Cross Corp's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-14%

Over the last year, the Depreciation & Amortization growth was -22%. The average annual Depreciation & Amortization growth rates for Green Cross Corp have been -24% over the past three years , -20% over the past five years , and -14% over the past ten years .

Back to Top